What next for the Sacklers? A pharma dynasty under siege
19 mins | Sep 12, 2018
They've filed for bankruptcy but haven't garnered any sympathy. We revisit this article explaining why.
David Crow writing in the Financial Times unfolds a special report into the scandal of a company accused of fuelling America’s opioid crisis
Get unlimited access free for 7 days, then $6.67/month (billed annually)